BERLIN (Reuters) – BioNTech and its partner for China, Shanghai Fosun Pharmaceutical, were granted approval for their COVID-19 vaccine that is adapted for the BA.4 and the BA.5 subvariants of Omicron for people aged 12 and older in Hong Kong, the German company said on Friday.
The vaccine is the first and currently only variant-adapted vaccine available as a booster dose for individuals 12 years and older that has been granted approval in Hong Kong, BioNTech said.
(Reporting by Kirsti Knolle; Editing by Miranda Murray)
